Pegfilgrastim Cbqv
Pronunciation: (yoo-DEN-ih-kuh).
- Generic name
- pegfilgrastim-cbqv
- Brand names
- Pegstim, Pegasta, Lapelga, Udenyca, Fulphila, Pelgraz
- Drug class
- Colony Stimulating Factor (CSF); Hematopoietic Agent
Availability and supply rules vary by country
Trade names by country: India
Australia: · Full directory
What pegfilgrastim-cbqv is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how pegfilgrastim-cbqv works
Udenyca (pegfilgrastim-cbqv) is a long-acting, pegylated form of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It binds to specific cell surface receptors on hematopoietic cells, stimulating the proliferation, differentiation, and activation of neutrophil precursors. This leads to increased production and release of neutrophils from the bone marrow, reducing the duration of neutropenia following chemotherapy. (1)
What pegfilgrastim-cbqv is used for
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. (1)
To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]).
To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]). (1)
Before taking pegfilgrastim-cbqv
Do not take / not appropriate for
- Contraindicated in patients with a history of serious allergic reactions to pegfilgrastim, filgrastim, or any component of the product. (Contraindication) (1)
Tell your clinician about
(1)How to take pegfilgrastim-cbqv
- General Instructions: Udenyca is administered as a single subcutaneous injection, typically 24 hours after chemotherapy completion. Only a healthcare professional should administer the injection unless you have been trained to do so.. Adult Dosing: The recommended dose for adults is 6 mg given subcutaneously once per chemotherapy cycle.. Pediatric Dosing: For children, dosing is weight-based: 0.1 mg/kg up to a maximum of 6 mg per cycle.. Administration: Inject under the skin of the upper arm, abdomen, or thigh. Rotate injection sites to avoid irritation.. When To Seek Review: Do not use Udenyca during the 14 days before or within 24 hours after chemotherapy. Contact your prescriber promptly if you develop a serious allergic reaction or splenic rupture, and let them advise on whether to continue.. Storage: Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Allow to reach room temperature for 30 minutes before injection.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
If you miss a dose, contact your healthcare provider immediately for instructions. do not take an extra dose to make up for a missed injection.
Overdose
In case of overdose, seek emergency medical attention. Symptoms may include excessive white blood cell counts, bone pain, or splenic enlargement. Supportive care and monitoring are recommended. (1)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Bone pain
Incidence: Reported in the clinician-authored database; frequency not established
Nausea
Incidence: Reported in the clinician-authored database; frequency not established
Fatigue
Incidence: Reported in the clinician-authored database; frequency not established
Fever
Incidence: Reported in the clinician-authored database; frequency not established
Allergic reactions
Incidence: Reported in the clinician-authored database; frequency not established
Splenic rupture
Incidence: Reported in the clinician-authored database; frequency not established
Acute respiratory distress syndrome (ARDS)
Incidence: Reported in the clinician-authored database; frequency not established
Capillary leak syndrome
Incidence: Reported in the clinician-authored database; frequency not established
Serious warnings
Risk of splenic rupture, which can be fatal — serious
Symptoms: Risk of splenic rupture, which can be fatal. Serious allergic reactions may occur. May cause acute respiratory distress syndrome (ARDS). Risk of capillary leak syndrome. May trigger sickle cell crisis in susceptible individuals.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindicated in patients with a history of serious allergic reactions to pegfilgrastim, filgrastim, or any component of the product. Use with caution in patients with sickle cell disease due to risk of sickle cell crisis. Monitor for splenic enlargement and rupture, acute respiratory distress syndrome, and capillary leak syndrome.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | There are no significant drug-drug interactions reported with Udenyca. However, it should not be given concurrently with chemotherapy or radiation therapy. Always inform your healthcare provider about all medications and supplements you are taking. | (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
The FDA label states there are no adequate human data to establish whether UDENYCA is associated with a risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes; animal studies showed increased abortion rates at maternally toxic doses. Discuss use during pregnancy with the treating oncology/prescribing team. (1)
Breastfeeding
The FDA label states there is no information on the presence of pegfilgrastim-cbqv in human milk, its effects on the breastfed infant, or on milk production. Discuss breastfeeding with the prescriber. (1)
Children
Frequency: Not recommended for pediatric use. Weight Based: Safety not established in children. Max Daily Dose: Not recommended for pediatric use. Max Single Dose: Not recommended for pediatric use. Age Restrictions: Safety not established in children (1)
Renal_impairment
Renal: renal dysfunction (including end-stage renal disease) has no effect on pegfilgrastim pharmacokinetics per a dedicated PK study; no dose adjustment is required. Hepatic: the FDA label does not include specific hepatic-impairment dosing studies for UDENYCA; as a large protein biologic cleared primarily via neutrophil-mediated and renal pathways rather than hepatic metabolism, no dose adjustment is specified, but the prescriber should still individualise care in significant hepatic disease. (1)
Hepatic_impairment
Renal: renal dysfunction (including end-stage renal disease) has no effect on pegfilgrastim pharmacokinetics per a dedicated PK study; no dose adjustment is required. Hepatic: the FDA label does not include specific hepatic-impairment dosing studies for UDENYCA; as a large protein biologic cleared primarily via neutrophil-mediated and renal pathways rather than hepatic metabolism, no dose adjustment is specified, but the prescriber should still individualise care in significant hepatic disease. (1)
Monitoring
(1)Storage
Store UDENYCA prefilled syringes refrigerated at 2-8°C (36-46°F) in the original carton to protect from light; do not freeze. If needed, UDENYCA may be kept at room temperature (up to 25°C/77°F) for a limited time per the FDA label — check current product labeling for the exact permitted duration before administering.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Dose summary: 6 mg administered as a single subcutaneous injection once per chemotherapy cycle, typically given 24 hours after chemotherapy.
Renal context: A pharmacokinetic study in 30 subjects with varying degrees of renal dysfunction, including end-stage renal disease, found that renal dysfunction had no effect on the pharmacokinetics of pegfilgrastim. No dose adjustment is required based on renal function. (1)
Frequently asked questions
What is Udenyca used for?
Udenyca is used to reduce the risk of infection in people receiving chemotherapy that can lower white blood cell counts by helping the body produce more neutrophils.
How is Udenyca administered?
Udenyca is given as a single subcutaneous injection, usually by a healthcare professional, 24 hours after chemotherapy.
What are the most common side effects of Udenyca?
Common side effects include bone pain, muscle aches, headache, and redness or swelling at the injection site.
Can I use Udenyca if I am pregnant or breastfeeding?
Inform your doctor if you are pregnant or breastfeeding. Udenyca should only be used if clearly needed and after discussing risks and benefits with your healthcare provider.
What should I do if I miss a dose?
Contact your healthcare provider for instructions. do not take an extra dose to make up for a missed injection.
Are there any serious risks with Udenyca?
Yes, serious risks include splenic rupture, severe allergic reactions, acute respiratory distress syndrome, and capillary leak syndrome. Seek immediate medical attention if you experience severe symptoms.
Is Udenyca a chemotherapy drug?
No, Udenyca is not a chemotherapy drug. It is a supportive medication used to help your body recover from the effects of chemotherapy.
What happens if I take too much Udenyca?
Taking too much Udenyca may lead to an overproduction of white blood cells, potentially causing symptoms like bone pain, fatigue, or an enlarged spleen. While specific overdose symptoms are not well-defined, it is crucial to seek immediate emergency medical attention if an overdose is suspected. Always adhere to your prescribed dosage to ensure safety and efficacy.
Can I drink alcohol while taking Udenyca?
While there are no direct contraindications between Udenyca and alcohol, it is generally advisable to limit or avoid alcohol consumption. Alcohol can potentially exacerbate common side effects like fatigue or body aches, and may also impact the immune system's response. Always consult your healthcare provider for personalized advice regarding alcohol intake during your treatment with Udenyca.
Is Udenyca safe during pregnancy?
Udenyca's safety during pregnancy has not been definitively established, and it is categorized as a medication where the risks to the fetus cannot be ruled out. Therefore, it is crucial to consult your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. They can assess the potential benefits versus risks and recommend the most appropriate course of action for your specific situation.
What is the mechanism of action of pegfilgrastim-cbqv?
Udenyca (pegfilgrastim-cbqv) is a long-acting, pegylated form of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It binds to specific cell surface receptors on hematopoietic cells, stimulating the proliferation, differentiation, and activation of neutrophil precursors. This leads to increased production and release of neutrophils from the bone marrow, reducing the duration of neutropenia following chemotherapy. (1)
What is the generic name of Pegfilgrastim Cbqv?
The generic name is pegfilgrastim-cbqv. It is sold under brand names including Pegstim, Pegasta, Lapelga, Udenyca, Fulphila, Pelgraz.
What class of drug is pegfilgrastim-cbqv?
Pegfilgrastim Cbqv is classed as: Colony Stimulating Factor (CSF); Hematopoietic Agent.
References
- Udenyca Prescribing InformationMedGuideGlobal · United States · accessed 2026-08-03 · source 1
- UDENYCA (pegfilgrastim-cbqv) — FDA-approved prescribing informationU.S. National Library of Medicine, DailyMed · United States · accessed 2026-08-07 · source 2
- UDENYCA (PEGFILGRASTIM-CBQV) INJECTION, SOLUTION [ACCORD BIOPHARMA, INC.] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 3
- Pegfilgrastim Injection — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 4
- UDENYCA — FDA approval record (Drugs@FDA BLA761039)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 5
- pegfilgrastim-cbqv — RxNorm normalized drug concept (RXCUI 2102692)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 6
Brand names by country
Single-ingredient pegfilgrastim-cbqv names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
India
- Peg Religrast6 mg/0.6 mL · Reliance Life Science
- Peg Grafeel6 mg/0.6 mL · Dr Reddy's Laboratories Ltd
- Pegasta6 mg/0.6 mL · Intas Pharmaceuticals Ltd